Across TCGA pan-cancer cohorts, AGAP4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AGAP4 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher AGAP4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGAP4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, LUAD, and LIHC are the cancer types where AGAP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.208	0.541	.018	18	view →
LUAD	DFS	Median	All	0.272	0.666	.018	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
UCEC	DFS	Median	All	1.000	0.630	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: AGAP4 tumor-vs-normal RNA expression · all AGAP4 data types